IS6687A - Pýrasólafleiður - Google Patents

Pýrasólafleiður

Info

Publication number
IS6687A
IS6687A IS6687A IS6687A IS6687A IS 6687 A IS6687 A IS 6687A IS 6687 A IS6687 A IS 6687A IS 6687 A IS6687 A IS 6687A IS 6687 A IS6687 A IS 6687A
Authority
IS
Iceland
Prior art keywords
pýrasólafleiður
Prior art date
Application number
IS6687A
Other languages
English (en)
Icelandic (is)
Inventor
Blair Cooper Christopher
John Helal Christopher
Allen Sanner Mark
T. Wager Travis
Original Assignee
Pfizer Products Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Products Inc. filed Critical Pfizer Products Inc.
Publication of IS6687A publication Critical patent/IS6687A/is

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • C07D231/40—Acylated on said nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IS6687A 2000-08-31 2003-01-16 Pýrasólafleiður IS6687A (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22941500P 2000-08-31 2000-08-31
PCT/IB2001/001540 WO2002018346A1 (en) 2000-08-31 2001-08-24 Pyrazole derivatives and their use as protein kinase inhibitors

Publications (1)

Publication Number Publication Date
IS6687A true IS6687A (is) 2003-01-16

Family

ID=22861151

Family Applications (1)

Application Number Title Priority Date Filing Date
IS6687A IS6687A (is) 2000-08-31 2003-01-16 Pýrasólafleiður

Country Status (39)

Country Link
EP (1) EP1313710A1 (es)
JP (1) JP2004507526A (es)
KR (1) KR20030027093A (es)
CN (1) CN1518543A (es)
AP (1) AP2001002266A0 (es)
AR (1) AR035345A1 (es)
AU (1) AU2001280009A1 (es)
BG (1) BG107455A (es)
BR (1) BR0113574A (es)
CA (1) CA2420363A1 (es)
CR (1) CR6881A (es)
CZ (1) CZ2003468A3 (es)
DO (1) DOP2001000243A (es)
DZ (1) DZ3398A1 (es)
EA (1) EA200300205A1 (es)
EC (1) ECSP034480A (es)
EE (1) EE200300085A (es)
GT (1) GT200100179A (es)
HN (1) HN2001000192A (es)
HR (1) HRP20030140A2 (es)
HU (1) HUP0302669A3 (es)
IL (1) IL154016A0 (es)
IS (1) IS6687A (es)
MA (1) MA26946A1 (es)
MX (1) MXPA03001785A (es)
NO (1) NO20030958L (es)
NZ (1) NZ523656A (es)
OA (1) OA12368A (es)
PA (1) PA8528101A1 (es)
PE (1) PE20020470A1 (es)
PL (1) PL360742A1 (es)
PY (1) PY0121331A (es)
SK (1) SK2002003A3 (es)
SV (1) SV2002000618A (es)
TN (1) TNSN01132A1 (es)
UY (1) UY26909A1 (es)
WO (1) WO2002018346A1 (es)
YU (1) YU14703A (es)
ZA (1) ZA200301064B (es)

Families Citing this family (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE538794T1 (de) 1999-01-13 2012-01-15 Bayer Healthcare Llc Gamma carboxyarylsubstituierte diphenylharnstoffverbindungen als p38 kinasehemmer
RU2319693C9 (ru) 1999-01-13 2008-08-20 Байер Копэрейшн Производные мочевины (варианты), фармацевтическая композиция (варианты) и способ лечения заболевания, связанного с ростом раковых клеток (варианты)
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US6660731B2 (en) 2000-09-15 2003-12-09 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US6613776B2 (en) 2000-09-15 2003-09-02 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
DK1318997T3 (da) 2000-09-15 2006-09-25 Vertex Pharma Pyrazolforbindelser der er nyttige som proteinkinase-inhibitorer
US7473691B2 (en) 2000-09-15 2009-01-06 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US6610677B2 (en) 2000-09-15 2003-08-26 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
HUP0400639A3 (en) 2000-12-21 2010-03-29 Vertex Pharma Pyrazole compounds useful as protein kinase inhibitors and pharmaceutical compositions containing them
US20040198799A1 (en) * 2001-09-27 2004-10-07 Brondyk William H. Methods of increasing endogenous testosterone levels
US20030216396A1 (en) 2002-02-11 2003-11-20 Bayer Corporation Pyridine, quinoline, and isoquinoline N-oxides as kinase inhibitors
US7838541B2 (en) 2002-02-11 2010-11-23 Bayer Healthcare, Llc Aryl ureas with angiogenesis inhibiting activity
MY141867A (en) 2002-06-20 2010-07-16 Vertex Pharma Substituted pyrimidines useful as protein kinase inhibitors
JP2006501191A (ja) * 2002-07-17 2006-01-12 ファルマシア・イタリア・エス・ピー・エー キナーゼ阻害剤としてのヘテロ二環式ピラゾール誘導体
DE60308387T2 (de) 2002-08-02 2007-09-20 Vertex Pharmaceuticals Inc., Cambridge Pyrazolenthaltende zusammensetzungen und ihre verwendung als gsk-3 inhibitoren
EP1551809A1 (en) 2002-10-09 2005-07-13 Pfizer Products Inc. Pyrazole compounds for treatment of neurodegenerative disorders
US7582630B2 (en) * 2002-10-15 2009-09-01 Smithkline Beecham Corporation Pyradazine compounds as GSK-3 inhibitors
DE602004016964D1 (de) 2003-02-27 2008-11-20 Smithkline Beecham Corp Neue verbindungen
WO2004113274A2 (en) 2003-05-20 2004-12-29 Bayer Pharmaceuticals Corporation Diaryl ureas with kinase inhibiting activity
US7759382B2 (en) * 2003-06-05 2010-07-20 Elan Pharmaceuticals, Inc. Acylated amino acid amidyl pyrazoles and related compounds
GB0317127D0 (en) * 2003-07-22 2003-08-27 Astex Technology Ltd Pharmaceutical compounds
NZ544756A (en) * 2003-07-22 2009-09-25 Astex Therapeutics Ltd 3,4-Disubstituted 1H-pyrazole compounds and their use as cyclin dependent kinases (CDK) and glycogen synthase kinase-3 (GSK-3) modulators
RS52625B (sr) 2003-07-23 2013-06-28 Bayer Healthcare Llc Fluoro supstituisana omega-karboksiaril difenil urea za lečenje i prevenciju bolesti i stanja bolesti
BRPI0412820A (pt) * 2003-07-25 2006-09-26 Pfizer compostos de aminopirazol e utilização como inibidores de chk1
EP1689721B1 (en) * 2003-11-26 2010-07-14 Pfizer Products Inc. Aminopyrazole derivatives as gsk-3 inhibitors
CN1925855B (zh) 2003-12-19 2010-06-16 普莱希科公司 开发Ret调节剂的化合物和方法
US7244757B2 (en) * 2004-04-01 2007-07-17 Pfizer Inc Pyrazole-amine compounds for the treatment of neurodegenerative disorders
WO2005103010A2 (en) * 2004-04-21 2005-11-03 Astrazeneca Ab Pyrazole derivatives useful for the treatment of cancer
ATE517885T1 (de) 2004-04-30 2011-08-15 Bayer Healthcare Llc Substituierte pyrazolyl-harnstoff-derivate zur behandlung von krebs
US7498342B2 (en) 2004-06-17 2009-03-03 Plexxikon, Inc. Compounds modulating c-kit activity
EP1781637A1 (en) * 2004-06-29 2007-05-09 Rigel Pharmaceuticals, Inc. 2-substituted quinoline compounds and their uses as inhibitors of the ige receptor signaling cascade
US7491720B2 (en) 2004-10-29 2009-02-17 Banyu Pharmaceutical Co., Ltd. Aminopyridine derivatives having Aurora A selective inhibitory action
JP2008520713A (ja) 2004-11-17 2008-06-19 ミイカナ セラピューティクス インコーポレイテッド キナーゼ阻害剤
US8404718B2 (en) 2005-01-21 2013-03-26 Astex Therapeutics Limited Combinations of pyrazole kinase inhibitors
AR054425A1 (es) 2005-01-21 2007-06-27 Astex Therapeutics Ltd Sales de adicion de piperidin 4-il- amida de acido 4-(2,6-dicloro-benzoilamino) 1h-pirazol-3-carboxilico.
NZ561145A (en) 2005-02-04 2011-02-25 Astrazeneca Ab Pyrazolylaminopyridine derivatives useful as kinase inhibitors
US20090156582A1 (en) * 2005-02-09 2009-06-18 Tetsuya Tsukamoto Pyrazole Compound
SI1853588T1 (sl) 2005-02-16 2008-10-31 Astrazeneca Ab Kemične spojine
BRPI0610184A2 (pt) 2005-05-16 2012-09-25 Astrazeneca Ab composto, sal farmaceuticamente aceitável de um composto, processo para preparar um composto ou um sal farmaceuticamente aceitável do mesmo, uso de um composto ou um sal farmaceuticamente aceitável do mesmo, métodos para a inibição da atividade de trk, para o tratamento ou profilaxia de cáncer e para a produção de um efeito anti-proliferativo em um animal de sanque quente, e, composição farmacêutica
EP1741708A1 (en) 2005-06-28 2007-01-10 Sanofi-Aventis Deutschland GmbH Heteroaryl-substituted amides comprising an unsaturated or cyclic linker group, and their use as pharmaceuticals
EP2258359A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis by muscarinic receptor modulation with sabcomelin
JP2009506069A (ja) 2005-08-26 2009-02-12 ブレインセルス，インコーポレイティド ムスカリン性受容体調節による神経発生
CA2622352C (en) 2005-09-30 2014-05-27 Miikana Therapeutics, Inc. Substituted pyrazole compounds
JP2009512711A (ja) 2005-10-21 2009-03-26 ブレインセルス，インコーポレイティド Ｐｄｅ阻害による神経新生の調節
DK1945631T3 (da) 2005-10-28 2012-10-22 Astrazeneca Ab 4- (3-aminopyrazole) pyrimidinderivater til anvendelse som tyrosinkinaseinhibitorer til behandling af cancer
EP2314289A1 (en) 2005-10-31 2011-04-27 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
TW200734327A (en) 2005-11-03 2007-09-16 Vertex Pharma Aminopyrimidines useful as kinase inhibitors
US7572809B2 (en) * 2005-12-19 2009-08-11 Hoffmann-La Roche Inc. Isoquinoline aminopyrazole derivatives
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
AU2007249399A1 (en) 2006-05-09 2007-11-22 Braincells, Inc. Neurogenesis by modulating angiotensin
PT2086642E (pt) 2006-10-18 2014-09-30 Periness Ltd Dnase para o tratamento de subfertilidade masculina
EP2535336A1 (en) 2006-10-21 2012-12-19 Abbott GmbH & Co. KG Heterocyclic compounds and their use as glycogen synthase kinase 3 inhibitors
WO2008063888A2 (en) 2006-11-22 2008-05-29 Plexxikon, Inc. Compounds modulating c-fms and/or c-kit activity and uses therefor
US7737149B2 (en) * 2006-12-21 2010-06-15 Astrazeneca Ab N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-yl]-4-(3,5-dimethylpiperazin-1-yl)benzamide and salts thereof
JP2010516734A (ja) 2007-01-24 2010-05-20 グラクソ グループ リミテッド ３，５−ジアミノ−６−（２，３−ジクロロフェニル）−１，２，４−トリアジンまたはｒ（−）−２，４−ジアミノ−５−（２，３−ジクロロフェニル）−６−フルオロメチルピリミジンを含む医薬組成物
MX2010000617A (es) 2007-07-17 2010-05-17 Plexxikon Inc Compuestos y metodos para modulacion de cinasa, e indicaciones de estos.
WO2009017453A1 (en) * 2007-07-30 2009-02-05 Astrazeneca Ab New therapeutic combination of an antipsychotic and a gsk3 inhibitor 958
ES2393824T3 (es) 2007-09-21 2012-12-28 Array Biopharma, Inc. Derivados de piridin-2-il-amino-1,2,4-tiadiazol como activadores de glucoquinasa para el tratamiento de diabetes mellitus
WO2009130900A1 (ja) * 2008-04-24 2009-10-29 日本曹達株式会社 オキシム誘導体、中間体化合物および植物病害防除剤
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
EA031116B1 (ru) 2009-04-03 2018-11-30 Ф. Хоффманн-Ля Рош Аг КРИСТАЛЛИЧЕСКИЕ ПОЛИМОРФНЫЕ ФОРМЫ {3-[5-(4-ХЛОРФЕНИЛ)-1H-ПИРРОЛО[2,3-b]ПИРИДИН-3-КАРБОНИЛ]-2,4-ДИФТОРФЕНИЛ}АМИДА ПРОПАН-1-СУЛЬФОНОВОЙ КИСЛОТЫ
EP2488511A1 (en) * 2009-10-02 2012-08-22 Vertex Pharmaceuticals Incorporated Pyrazole inhibitors of phosphatidylinositol 3-kinase
UA105813C2 (uk) 2009-11-06 2014-06-25 Плексікон, Інк. Сполуки-інгібітори кіназ та фармацевтична композиція (варіанти)
MX336726B (es) 2010-09-27 2016-01-27 Abbott Gmbh & Co Kg Compuestos heterociclicos y su uso como inhibidores de la glucogeno sintasa quinasa-3.
US9090592B2 (en) 2010-12-30 2015-07-28 AbbVie Deutschland GmbH & Co. KG Heterocyclic compounds and their use as glycogen synthase kinase-3 inhibitors
PL2672967T3 (pl) 2011-02-07 2019-04-30 Plexxikon Inc Związki i sposoby modulacji kinaz i wskazania ku temu
TWI558702B (zh) 2011-02-21 2016-11-21 普雷辛肯公司 醫藥活性物質的固態形式
US9150570B2 (en) 2012-05-31 2015-10-06 Plexxikon Inc. Synthesis of heterocyclic compounds
MX2016001934A (es) * 2013-08-16 2016-06-10 Merck Patent Gmbh Derivados de ciclopentilamina 3-sustituidos.
CN106580986B (zh) * 2016-11-28 2017-09-15 王保亮 一种治疗少弱精子症的药物组合物
EA202191852A1 (ru) 2018-12-31 2022-03-18 Биомеа Фьюжн, Ллс Необратимые ингибиторы взаимодействия менин-mll
EP3906029A4 (en) 2018-12-31 2022-09-21 Biomea Fusion, LLC INHIBITORS OF MENIN-MLL INTERACTION
JP7094456B2 (ja) * 2019-01-31 2022-07-01 ファイザー・インク Ｃｄｋ２阻害剤
US12479816B2 (en) 2019-02-08 2025-11-25 University of Pittsburgh—of the Commonwealth System of Higher Education 20-HETE formation inhibitors
AU2021359129A1 (en) * 2020-10-16 2023-06-01 Proxygen Gmbh Heterocyclic cullin ring ubiquitin ligase compounds and uses thereof
TW202229268A (zh) * 2020-12-22 2022-08-01 大陸商上海拓界生物醫藥科技有限公司 Ｃｄｋ２抑制劑及其製備方法
KR20240020735A (ko) 2021-05-07 2024-02-15 카이메라 쎄라퓨틱스 인코포레이티드 Cdk2 분해제 및 그 용도
CA3219348A1 (en) * 2021-05-27 2022-12-01 Anthony B. Pinkerton Checkpoint kinase 1 (chk1) inhibitors and uses thereof
KR20240046167A (ko) 2021-06-28 2024-04-08 블루프린트 메디신즈 코포레이션 Cdk2 저해제
TW202317564A (zh) * 2021-07-01 2023-05-01 大陸商上海拓界生物醫藥科技有限公司 Cdk2抑制劑及其製備方法和用途
AU2022325861A1 (en) 2021-08-11 2024-02-29 Biomea Fusion, Inc. Covalent inhibitors of menin-mll interaction for diabetes mellitus
IL310717A (en) 2021-08-20 2024-04-01 Biomea Fusion Inc Crystalline form of N-[4-[4-(4-morpholinyl)-7H-PYRROLO[2,3-D]PYRIMIDIN-6-YL]PHENYL]-4-[[3(R)-[(1-OXO ] -2-PROPEN-1-YL)AMINO]-1-PIPERIDINYL]METHYL]-2-PYRIDINECARBOXAMIDE, IRREVERSIBLE MENIN-MLL INHIBITOR FOR CANCER TREATMENT
TW202325280A (zh) * 2021-11-09 2023-07-01 大陸商上海拓界生物醫藥科技有限公司 一種胺基吡唑衍生物及其製備方法和用途
WO2023092088A1 (en) * 2021-11-19 2023-05-25 Blueprint Medicines Corporation Cdk2 inhibitors and methods of making and using same
WO2023239629A1 (en) * 2022-06-06 2023-12-14 Plexium, Inc. Compounds and pharmaceutical compositions that degrade cdk2
TW202430528A (zh) 2023-01-18 2024-08-01 美商拜歐米富士恩股份有限公司 Ｎ－［４－［４－（４－嗎啉基）－７ｈ－吡咯並［２，３－ｄ］嘧啶－６－基］苯基］－４－［［３（ｒ）－［（１－氧代－２－丙烯－１－基）氨基］－１－哌啶基］甲基］－２－吡啶甲醯胺的結晶形式作為ｍｅｎｉｎ－ｍｌｌ相互作用的共價抑制劑
WO2026024674A1 (en) 2024-07-22 2026-01-29 Genesis Therapeutics, Inc. Methods of treating skp2-associated cancers

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1047418B1 (en) * 1997-12-22 2005-07-27 Bayer Pharmaceuticals Corp. Inhibition of raf kinase using substituted heterocyclic ureas
KR100579792B1 (ko) * 1998-05-13 2006-05-12 동화약품공업주식회사 신규 2,5-피리딘디카복실산 유도체
GB9811427D0 (en) * 1998-05-29 1998-07-22 Zeneca Ltd Chemical compounds
US6958333B1 (en) * 1999-07-26 2005-10-25 Banyu Pharmaceutical Co., Ltd. Biarylurea derivatives
GEP20053476B (en) * 1999-08-12 2005-03-25 Upjohn Co 3(5)-Amino-Pyrazole Derivatives, Process for Their Preparation and Their Use as Antitumor Agents
US6387900B1 (en) * 1999-08-12 2002-05-14 Pharmacia & Upjohn S.P.A. 3(5)-ureido-pyrazole derivatives process for their preparation and their use as antitumor agents
IL149103A0 (en) * 1999-11-30 2002-11-10 Pfizer Prod Inc 2,4-diaminopyrimidine compounds useful as immunosuppressants
JP2004501083A (ja) * 2000-04-18 2004-01-15 アゴーロン・ファーマシューティカルズ・インコーポレイテッド プロテインキナーゼを阻害するためのピラゾール

Also Published As

Publication number Publication date
PY0121331A (es) 2004-06-01
EP1313710A1 (en) 2003-05-28
BR0113574A (pt) 2003-07-22
TNSN01132A1 (fr) 2005-11-10
EE200300085A (et) 2004-12-15
HN2001000192A (es) 2001-08-28
SV2002000618A (es) 2002-10-24
AR035345A1 (es) 2004-05-12
AP2001002266A0 (en) 2001-09-30
BG107455A (bg) 2003-09-30
HUP0302669A2 (hu) 2003-12-29
AU2001280009A1 (en) 2002-03-13
DZ3398A1 (fr) 2002-03-07
ZA200301064B (en) 2004-04-19
KR20030027093A (ko) 2003-04-03
GT200100179A (es) 2002-04-22
EA200300205A1 (ru) 2003-06-26
HUP0302669A3 (en) 2004-03-29
CN1518543A (zh) 2004-08-04
PE20020470A1 (es) 2002-06-18
MXPA03001785A (es) 2003-06-04
PL360742A1 (en) 2004-09-20
WO2002018346A1 (en) 2002-03-07
UY26909A1 (es) 2002-03-22
ECSP034480A (es) 2003-03-31
CR6881A (es) 2004-03-11
NO20030958D0 (no) 2003-02-28
NZ523656A (en) 2004-11-26
OA12368A (en) 2004-04-13
SK2002003A3 (en) 2004-04-06
IL154016A0 (en) 2003-07-31
YU14703A (sh) 2006-05-25
JP2004507526A (ja) 2004-03-11
DOP2001000243A (es) 2002-10-15
MA26946A1 (fr) 2004-12-20
CZ2003468A3 (cs) 2004-05-12
NO20030958L (no) 2003-02-28
HRP20030140A2 (en) 2003-04-30
CA2420363A1 (en) 2002-03-07
PA8528101A1 (es) 2002-07-30

Similar Documents

Publication Publication Date Title
ATE290000T1 (de) Muscarinagonisten
ATE252099T1 (de) Biarylcarboxamide
IS6687A (is) Pýrasólafleiður
DE10136334B8 (de) Hochgeschwindigkeitsvertikalresonatoroberflächenemissionslaser
ATE312098T1 (de) Thiazinoxazolidinon
ATA2932001A (de) Schneefräse
DE50108963D1 (de) Schlauchklemme
DE50106867D1 (de) Kugelgelenk
DE50108226D1 (de) Vordralldüsenträger
DE50104056D1 (de) Gewichtsmanschette
DE50100710D1 (de) Wischblatt
ATE262530T1 (de) Indolochinazolinone
DE50104651D1 (de) Fahrzeugfaltverdeck
DE10192638T1 (de) Bohrstangenladevorrichtung
AR028336A1 (es) 4-hidroxi-tetrahidropiridonas fenilsubstituidas
DE50109748D1 (de) Hydrolager
ATE509008T1 (de) Sulfonylguanidine
DE10196064T1 (de) Halbleiterfotodektionsgerät
DE50100817D1 (de) Kugelgelenk
DE50011511D1 (de) Blowby-Heizung
DE10052925B4 (de) Schaukelbett
ATE476423T1 (de) Benzoylpyridazine
DE10195909T1 (de) Viehfüttervorrichtung
AR027982A1 (es) Aril- y heteroarilsulfonatos
DE50109335D1 (de) Rohrverleger